Benchmark lowered the firm's price target on HeartBeam to $5 from $8 and keeps a Speculative Buy rating on the shares after "a solid update" provided with Q1 results. However, while the recent $11.5M equity offering at 80c per share funds a runway at least through this year, the firm's prior model had not assumed this level of dilution, the analyst tells investors.
